Secondary malignancies in chronic myeloid leukemia patients after imatinib-based treatment: long-term observation in CML Study IV. (Q36974374)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26859076%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

title

Secondary malignancies in chronic myeloid leukemia patients after imatinib-based treatment: long-term observation in CML Study IV (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26859076%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

main subject

chronic myeloid leukemia

0 references

author

Michael Lauseker

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26859076%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

Stefan W. Krause

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26859076%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

Andreas Hochhaus

26

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26859076%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

author name string

M B Miranda

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26859076%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

M-P Kraus

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26859076%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

U Proetel

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26859076%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

B Hanfstein

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26859076%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

A Fabarius

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26859076%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

G M Baerlocher

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26859076%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

D Heim

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26859076%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

D K Hossfeld

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26859076%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

H-J Kolb

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26859076%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

C Nerl

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26859076%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

T H Brümmendorf

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26859076%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

W Verbeek

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26859076%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

A A Fauser

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26859076%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

O Prümmer

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26859076%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

K Neben

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26859076%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

U Hess

18

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26859076%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

R Mahlberg

19

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26859076%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

C Plöger

20

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26859076%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

M Flasshove

21

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26859076%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

B Rendenbach

22

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26859076%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

W-K Hofmann

23

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26859076%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

M C Müller

24

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26859076%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

M Pfirrmann

25

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26859076%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

J Hasford

27

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26859076%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

R Hehlmann

28

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26859076%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

S Saußele

29

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26859076%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

publication date

9 February 2016

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26859076%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26859076%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

volume

30

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26859076%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

page(s)

1255-1262

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26859076%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26859076%20AND%20SRC:MED&resulttype=core&format=json

Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International

7 March 2020

copyright license

start time

9 February 2016

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

exact match

https://scigraph.springernature.com/pub.10.1038/leu.2016.20

0 references

cites work

Defining AML and MDS second cancer risk dynamics after diagnoses of first cancers treated or not with radiation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4895174

Impact of comorbidities on overall survival in patients with chronic myeloid leukemia: results of the randomized CML study IV.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4895174

Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4895174

Occurrence of secondary malignancies in chronic myeloid leukemia during therapy with imatinib mesylate-single institution experience

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4895174

Second primary malignancies in chronic myeloid leukemia

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4895174

Tyrosine kinase inhibitor usage, treatment outcome, and prognostic scores in CML: report from the population-based Swedish CML registry

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4895174

European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4895174

Second cancer incidence and cancer mortality among chronic lymphocytic leukaemia patients: a population-based study.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4895174

Malignancies occurring during therapy with tyrosine kinase inhibitors (TKIs) for chronic myeloid leukemia (CML) and other hematologic malignancies

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4895174

Multicenter Independent Assessment of Outcomes in Chronic Myeloid Leukemia Patients Treated With Imatinib

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4895174

Secondary solid cancers after allogeneic hematopoietic cell transplantation using busulfan-cyclophosphamide conditioning

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4895174

Are chronic myeloid leukemia patients more at risk for second malignancies? A population-based study

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4895174

Risk factors for lymphoproliferative disorders after allogeneic hematopoietic cell transplantation

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4895174

Other malignancies in chronic lymphocytic leukemia/small lymphocytic lymphoma

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4895174

Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4895174

Effects of imatinib on normal hematopoiesis and immune activation.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4895174

Vascular and neoplastic risk in a large cohort of patients with polycythemia vera

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4895174

Second primary neoplasms among 53 159 haematolymphoproliferative malignancy patients in Sweden, 1958-1996: a search for common mechanisms

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4895174

Estimation of failure probabilities in the presence of competing risks: new representations of old estimators

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4895174

Impact of unbalanced minor route versus major route karyotypes at diagnosis on prognosis of CML.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4895174

Incidence of second malignancies during treatment of chronic myeloid leukemia with tyrosine kinase inhibitors in the Czech Republic and Slovakia

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4895174

Solid cancers after bone marrow transplantation.

27 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4895174

Proportion of disease caused or prevented by a given exposure, trait or intervention

27 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4895174

Second malignancies following treatment of chronic myeloid leukaemia in the tyrosine kinase inhibitor era.

27 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4895174

Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-study IV.

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4895174

Chronic myeloproliferative neoplasms and subsequent cancer risk: a Danish population-based cohort study

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4895174

Second cancer risk after chemotherapy for Hodgkin's lymphoma: a collaborative British cohort study

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4895174

Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4895174

Tolerability-adapted imatinib 800 mg/d versus 400 mg/d versus 400 mg/d plus interferon-α in newly diagnosed chronic myeloid leukemia.

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4895174

Second malignancies in essential thrombocythemia (ET): a retrospective analysis of 331 patients with long-term follow-up from a single institution.

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4895174

Epidemiological analysis of second primary malignancies in more than 9500 patients treated with imatinib

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4895174

Unexpected occurrence of second malignancies in patients treated with interferon followed by imatinib mesylate for chronic myelogenous leukemia

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4895174

Statistical methods in cancer research. Volume IV. Descriptive epidemiology.

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4895174

Nonparametric Estimation from Incomplete Observations

4 September 2018

1 reference

Crossref

https://api.crossref.org/works/10.1038%2FLEU.2016.20

Long-term survival in chronic myelocytic leukemia after a first primary malignancy

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1038%2FLEU.2016.20

21 January 2018

A sense-abl response?

1 reference

Crossref

https://api.crossref.org/works/10.1038%2FLEU.2016.20

Secondary malignancies after bone marrow transplantation in adults

21 January 2018

1 reference

12 December 2020

Second malignancies in patients with essential thrombocythaemia treated with busulphan and hydroxyurea: long-term follow-up of a randomized clinical trial

1 reference

12 December 2020

Cutaneous and mucosal neoplasms in bone marrow transplant recipients

1 reference

12 December 2020

Meta-analysis of second cancer risk after radiotherapy among childhood cancer survivors

1 reference

12 December 2020

Second cancer after radiotherapy, 1981-2007

1 reference

12 December 2020

Second malignancy after Hodgkin disease treated with radiation therapy with or without chemotherapy: long-term risks and risk factors

1 reference

12 December 2020

Identifiers

DOI

10.1038/LEU.2016.20

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26859076%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26859076%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26859076%20AND%20SRC:MED&resulttype=core&format=json